STTK Shattuck Labs, Inc.
Price Chart
Executive Summary
Shattuck Labs reported Q1 2026 net loss of $0.13 per share, slightly better than consensus of -$0.14, but the company remains pre-revenue with no product sales. The key update is completion of Phase 1 enrollment for SL-325, with data expected in Q2 2026. Cash position strengthened to $90.4M, extending runway into 2029.
Actionable Insight
Monitor Phase 1 SL-325 data release in Q2 2026; positive data could catalyze significant upside. No near-term revenue catalysts.
Key Facts
- Phase 1 trial of SL-325 enrollment complete; data expected Q2 2026
- Cash and investments $90.4M as of March 31, 2026, up from $54.2M at Dec 31, 2025
- Net loss $14.8M ($0.13/share) vs $13.7M ($0.27/share) in Q1 2025
- No revenue reported in Q1 2026 or Q1 2025
- Cash runway expected to fund operations into 2029 assuming warrant exercise
Financial Impact
Net loss per share -$0.13 vs consensus -$0.14 (7.1% beat), but pre-revenue, cash burn increases slightly
Risk Factors
- Phase 1 data may disappoint, delaying Phase 2 initiation
- Cash burn may increase with Phase 2 costs, potentially requiring additional financing
- No approved products; dependent on clinical trial success
Market Snapshot
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-031643 |
| Document: sttk-20260507.htm | 0001628280-26-031643 |
| Document: 0001628280-26-031643-index-headers.html | 0001628280-26-031643 |
| Document: 0001628280-26-031643-index.html | 0001628280-26-031643 |
| Document: 0001628280-26-031643.txt | 0001628280-26-031643 |
| 8-K Data (Synthetic) | 0001628280-26-031643 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 11, 2026
3d ago
|
8-K
| $4.13 awaiting T+1 | awaiting T+1 | — | $4.94 (−19.61%) |
|
Jun 11, 2026
3d ago
|
Institutional Cluster
| $4.13 awaiting T+1 | awaiting T+1 | — | $4.94 (−19.61%) |
|
Jun 11, 2026
3d ago
|
424B5
| $4.13 awaiting T+1 | awaiting T+1 | — | $4.94 (−19.61%) |
|
Jun 10, 2026
5d ago
|
Press Release
| $4.27 awaiting T+1 | awaiting T+1 | — | $4.94 (−15.69%) |
|
Jun 9, 2026
5d ago
|
424B5
| $4.27 awaiting T+1 | awaiting T+1 | — | $4.94 (−15.69%) |
|
Jun 9, 2026
5d ago
|
8-K
| $4.27 awaiting T+1 | awaiting T+1 | — | $4.94 (+15.69%) |
|
Jun 2, 2026
12d ago
|
8-K
| $4.75 $4.80 | ▲ +1.05% | ▲ +0.65% | $4.94 (+4.00%) |
|
May 15, 2026
4w ago
|
Insider Cluster
| $6.26 $5.97 | ▼ −4.63% | ▼ −4.57% | $4.94 (−21.09%) |
|
May 12, 2026
4w ago
|
Insider Cluster
| $6.62 $6.75 | ▲ +1.96% | ▲ +1.39% | $4.94 (−25.38%) |
|
May 7, 2026
5w ago
|
8-K
| $6.26 $6.85 | ▲ +9.42% | ▲ +8.59% | $4.94 (−21.09%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access